


Yufeng Zheng, Xiaoxue Xu, Zhigang Xu,
Junqiang Wang, and Hong Cai

Metallic Biomaterials

New Directions and Technologies



Metallic Biomaterials

Metallic Biomaterials

New Directions and Technologies

*Yufeng Zheng, Xiaoxue Xu, Zhigang Xu, Junqiang Wang,
and Hong Cai*

Authors

Prof. Yufeng Zheng

Peking University
Department of Materials Science and
Engineering
College of Engineering
No. 5 Yi-He-Yuan Road, Haidian District
100871 Beijing
China

Dr. Xiaoxue Xu

Macquarie University
Dept. of Chemistry and Biomol. Sciences
Balaclava Road
North Ryde, NSW
2109 Sydney
Australia

Dr. Zhigang Xu

North Carolina A&T State University
NSF ERC for Revolutionizing Metallic
Biomaterials
NSF Center for Advanced Materials and Smart
Structures
1601 East Market Street
27411 NC
United States

Prof. Junqiang Wang

Chinese Academy of Sciences
Ningbo Institute of Materials Technology and
Engineering
1219 Zhongguan West Road
Ningbo City
Zhejiang Province 315201
China

Dr. Hong Cai

Peking University Third Hospital
Department of Orthopedics
No.49 North Garden Road
100191 Beijing
China

Cover

prosthesis in the background
©fotolia_Alexandr Mitiuc

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-34126-9

ePDF ISBN: 978-3-527-34243-3

ePub ISBN: 978-3-527-34245-7

Mobi ISBN: 978-3-527-34246-4

oBook ISBN: 978-3-527-34244-0

Cover Design Adam Design

Typesetting SPi Global, Chennai, India

Printing and Binding Markono

Printed on acid-free paper

Contents

Preface *xi*

About the Authors *xiii*

1	Introduction	<i>1</i>
1.1	Traditional Metallic Biomaterials	<i>1</i>
1.2	Revolutionizing Metallic Biomaterials and Their New Biofunctions	<i>3</i>
1.2.1	What are Revolutionizing Metallic Biomaterials?	<i>3</i>
1.2.2	Antibacterial Function	<i>3</i>
1.2.3	Promotion of Osteogenesis	<i>5</i>
1.2.4	Reduction of In-stent Restenosis	<i>8</i>
1.2.5	MRI Compatibility	<i>9</i>
1.2.6	Radiopacity	<i>10</i>
1.2.7	Self-Adjustment of Young's Modulus for Spinal Fixation Applications	<i>10</i>
1.3	Technical Consideration on Alloying Design of Revolutionizing Metallic Biomaterials	<i>10</i>
1.3.1	Evolution of Mechanical Properties with Implantation Time	<i>10</i>
1.3.2	Biocorrosion or Biodegradation Behavior and Control on Ion Release	<i>14</i>
1.4	Novel Process Technologies for Revolutionizing Metallic Biomaterials	<i>16</i>
1.4.1	3D Printing	<i>17</i>
1.4.2	Safety and Effectiveness of Biofunctions	<i>17</i>
1.4.3	Severe Plastic Deformation	<i>20</i>
	References	<i>20</i>
2	Introduction of the Biofunctions into Traditional Metallic Biomaterials	<i>31</i>
2.1	Antibacterial Metallic Biomaterials	<i>31</i>
2.1.1	Antibacterial Metals	<i>31</i>
2.1.2	Antibacterial Stainless Steels	<i>33</i>
2.1.2.1	Ag-Bearing Antibacterial Stainless Steels	<i>33</i>
2.1.2.2	Cu-Bearing Antibacterial Stainless Steels	<i>34</i>
2.1.2.3	Other Antibacterial Stainless Steels	<i>36</i>
2.1.3	Antibacterial Ti Alloys	<i>37</i>
2.1.3.1	Antibacterial Ti–Ag Alloys	<i>37</i>

2.1.3.2	Antibacterial Ti–Cu Alloys	37
2.1.3.3	Antibacterial TiNi-Based Alloys	38
2.1.3.4	Surface-Modified Ti Alloys with Antibacterial Property	38
2.1.4	Antibacterial Mg Alloys	39
2.1.5	Antibacterial Bulk Metallic Glasses	40
2.2	MRI Compatibility of Metallic Biomaterials	40
2.2.1	MRI Compatibility of Traditional Metallic Biomaterials	44
2.2.2	MRI-Compatible Zr Alloys	44
2.2.3	MRI-Compatible Nb Alloys	46
2.2.4	Other MRI-Compatible Alloys	47
2.3	Radiopacity of Metallic Biomaterials	47
2.3.1	Stainless Steel Stents	48
2.3.2	Co–Cr Stents	48
2.3.3	Nitinol Stents	49
2.3.4	Ta Stents	49
2.3.5	Other Metallic Stents	49
	References	50
3	Development of Mg-Based Degradable Metallic Biomaterials	59
3.1	Background	59
3.2	Mg-Based Alloy Design and Selection Considerations	60
3.2.1	Biodegradation	60
3.2.2	Biocompatibility	64
3.2.3	Considerations in Mg-Based Alloy Design	64
3.2.3.1	Mechanical Property Requirements	64
3.2.3.2	Material Compositional Design	65
3.2.3.3	Toxicity and Degradation Consideration	66
3.2.4	Methods to Improve Mechanical Property	67
3.2.4.1	<i>In Situ</i> Strengthening	67
3.2.4.2	Post-processing	75
3.3	State of the Art of the Mg-Based Alloy Material Research	83
3.3.1	Pure Mg	83
3.3.2	Mg-Based Alloys with Essential Elements	84
3.3.2.1	Mg–Ca-Based Alloys	84
3.3.2.2	Mg–Si- and Mg–Sr-Based Alloys	85
3.3.3	Mg-Based Alloys with High Strength	86
3.3.3.1	Mg–Zn-Based Alloys	87
3.3.3.2	Mg–RE-Based Alloys	87
3.3.4	Mg-Based Alloys with Special Biofunctions	88
3.3.5	Mg-Based Alloys with Improved Corrosion Resistance	90
3.3.6	Mg-Based Alloys with Bioactive Surfaces	91
3.3.6.1	Drug-Releasing Coatings	91
3.3.6.2	Biomimetic Coatings	91
3.4	State of the Art of Medical Mg-Based Alloy Device Research	92
3.4.1	Cardiovascular Devices	92
3.4.2	Orthopedic Devices	94

3.5	Challenges and Opportunities for Mg-Based Biomedical Materials and Devices	97
	References	98
4	Development of Fe-Based Degradable Metallic Biomaterials	113
4.1	Background	113
4.2	Pure Iron	114
4.2.1	Mechanical Properties of Pure Iron	114
4.2.2	Metabolism and Toxicity of Pure Iron	114
4.2.2.1	The Distribution of Iron in Human Body	114
4.2.2.2	Physiological Function of Iron in Human Body	114
4.2.2.3	Iron Absorption	114
4.2.2.4	The Maintenance of Iron Balance	117
4.2.2.5	The Toxicity of Iron	118
4.2.3	Basic Properties of Pure Iron	118
4.2.3.1	Effects of Processing Technologies on the Microstructure of Pure Iron	118
4.2.4	Degradation Behavior of Pure Iron in the Physiological Environment	119
4.2.5	<i>In Vitro</i> Experiments of Pure Iron	121
4.2.6	<i>In Vivo</i> Experiments of Pure Iron	123
4.3	Iron Alloys	127
4.4	Iron-Based Composites	139
4.4.1	Compositing with Metals	139
4.4.2	Compositing with Nonmetallic Materials	141
4.4.3	<i>In Vitro</i> Biocompatibility of Iron-Based Composites	142
4.5	Surface Modification of Iron-Based Materials	144
4.5.1	Surface Modification for Improving Biocompatibility	144
4.5.2	Surface Modification for Regulating Degradation Behavior	147
4.6	New Fabrication Technologies for Iron-Based Materials	150
4.6.1	Electroforming	150
4.6.2	Equal Channel Angular Pressing	150
4.6.3	Metal Injection Molding	151
4.6.4	Cold Gas Dynamic Spraying	151
4.6.5	3D Printing	153
4.7	Outlook	154
	References	156
5	Development of Zn-Based Degradable Metallic Biomaterials	161
5.1	Backgrounds	161
5.2	Body Zn Distribution and Mobilization	162
5.3	The Physiological Function of Zn	162
5.4	State of the Art of the Zn-Based Alloy Material Research	164
5.4.1	Pure Zn	164
5.4.2	Binary Zn-Based Alloys	165
5.4.2.1	The Microstructure of Binary Zn-Based Alloy	166

5.4.2.2	The Mechanical Properties of Binary Zn-Based Alloy	167
5.4.2.3	The Degradation Behavior of Binary Zn-Based Alloys	167
5.4.2.4	The Biocompatibility of Binary Zn-Based Alloys	170
5.4.3	Ternary Zn-Based Alloys	174
5.4.3.1	The Microstructure of Ternary Zn-Based Alloys	174
5.4.3.2	The Mechanical Properties of Ternary Zn-Based Alloys	175
5.4.3.3	The Degradation Behavior of Ternary Zn-Based Alloys	176
5.4.3.4	The Biocompatibility of Ternary Zn-Based Alloys	178
5.4.4	Zn-Based Composites	178
5.4.4.1	Zn–ZnO Composites	178
5.4.4.2	Zn–Nanodiamond Composites	182
5.5	Challenges and Opportunities for Zn-Based Biomedical Materials and Devices	182
	References	185
6	Development of Bulk Metallic Glasses for Biomedical Application	189
6.1	Background	189
6.1.1	Oxide Glasses as Biomaterials	189
6.1.2	Bulk Metallic Glasses	191
6.1.3	Fabrication of Bulk Metallic Glasses	191
6.1.4	Properties of Bulk Metallic Glasses	193
6.2	Nonbiodegradable Bulk Metallic Glasses	196
6.2.1	Ti-Based Bulk Metallic Glasses	197
6.2.2	Zr-Based Bulk Metallic Glasses	198
6.2.3	Fe-Based Bulk Metallic Glasses	201
6.3	Biodegradable Bulk Metallic Glasses	202
6.3.1	Mg-Based Bulk Metallic Glasses	202
6.3.2	Ca-Based Bulk Metallic Glasses	207
6.3.3	Zn-Based Bulk Metallic Glasses	208
6.3.4	Sr-Based Bulk Metallic Glasses	209
6.4	Perspectives on Future R&D of Bulk Metallic Glass for Biomedical Application	209
6.4.1	How to Design Better Bulk Metallic Glasses	209
6.4.1.1	Functional Minor Alloying Elements	209
6.4.1.2	The Glass-Forming Ability	210
6.4.2	Surface Modification of Bulk Metallic Glasses	211
6.4.3	How to Manufacture Medical Devices Using Bulk Metallic Glasses	211
6.4.4	Future Biomedical Application Areas of Bulk Metallic Glass	211
	References	213
7	Development of Bulk Nanostructured Metallic Biomaterials	223
7.1	Background	223
7.1.1	Processing Methods	224
7.1.2	Property Variation	225
7.1.3	Structure–Property Relationship	228

7.2	Representative Bulk Nanostructured Metallic Biomaterials	230
7.2.1	Pure Ti	230
7.2.2	Ti Alloys	235
7.2.3	Stainless Steels	238
7.2.4	Co–Cr–Mo Alloy	239
7.2.5	Mg Alloys	243
7.2.6	Pure Fe and Other Fe-Based Alloys	244
7.2.7	Pure Cu	244
7.2.8	Pure Ta	244
7.2.9	Pure Zr	245
7.3	Future Prospect on Bulk Nanostructured Metallic Biomaterials	245
	References	246
8	Titanium Implants Based on Additive Manufacture	255
8.1	Introduction	255
8.2	AM Technologies Applicable for Ti-Based Alloys	256
8.2.1	Powder Materials Used in AM Technology	257
8.2.2	Architecture Design in AM Technology	257
8.2.3	Processing Methods of AM Technology	259
8.2.4	Posttreatment of AM Technology	263
8.2.5	Surface Forming Quality of AM Technology	264
8.3	Microstructure and Performance Evaluation of Ti-Based Alloys Fabricated by AM Technology	265
8.3.1	Microstructure of Ti-Based Alloys Fabricated by AM Technology	265
8.3.2	Mechanical Properties of Ti-Based Alloys Fabricated by AM Technology	267
8.3.3	<i>In Vitro</i> Biological Evaluation of Ti-Based Implants Fabricated by AM Technology	273
8.3.4	Animal Experiments of Ti-Based Implants Fabricated by AM Technology	275
8.3.5	Clinical Trials of Ti-Based Implants Fabricated by AM Technology	277
8.4	Prospects	278
	References	285
9	Future Research on Revolutionizing Metallic Biomaterials	293
9.1	Tissue Engineering Scaffolds with Revolutionizing Metallic Biomaterials	293
9.2	Building Up of Multifunctions for Revolutionizing Metallic Biomaterials	296
9.3	Intelligentization for Revolutionizing Metallic Biomaterials	300
	References	304

Preface

Traditional metallic biomaterials, including stainless steels, Co-based alloys, and titanium and its alloys, are mainly used for replacing failed hard tissue, for example, artificial hip and knee joints, bone plates, and dental implants. The key issues for the material design involve excellent mechanical property, corrosion resistance, and biocompatibility, and in body fluids, these biomaterials act as bioinert implants that occasionally exhibit surface bioactivity after a certain surface pretreatment. Since 2000, new revolutionizing metallic biomaterials have been developed such as antibacterial functionalized stainless steel and biodegradable metals (Mg based and Fe based) with bioactivity. Novel structured metallic biomaterials have been fabricated to improve performance, such as amorphous bulk metallic glasses with lower elastic modulus but high elastic limit; nanocrystalline pure metals and alloys prepared by severe plastic deformation that exhibit improved ion release behavior or enhanced bone formability; precisely controlled porous structures for three-dimensional-printed, custom-designed bone scaffold design; and bioceramics and biopolymers with improved mechanical properties and biocompatibility. All these newly emerging revolutionized metallic biomaterials have future clinical applications, and their development shifts the original principle for alloying element selection during alloy design from passive inhibition of the released toxic metal ions (Ni in biomedical TiNi alloy) during the implantation period to the active introduction of certain metal elements with specific biofunctions into the material (e.g., adding osteoinduced Zn, Ca, and Sr into Mg to enhance bone formability) and brings new vitality in the fields of dentistry, orthopedics, cardiology, interventional therapy, gynecology, and hepatobiliary surgery. Diverse surface treatment technologies have further improved the performance of these new metallic biomaterials within the human body, making them more suitable for next-generation engineered tissue reconstruction scaffold. These metallic biomaterials as an emerging area in the twenty-first century and their bioactivities and biofunctions, including biodegradation, antibacterial and osteoinductive functions, radiopacity, and MRI compatibility, are the emphasis of this book.

The book comprises nine chapters in total. The first chapter, "Introduction," illustrates the differences between revolutionizing and traditional metallic biomaterials and their technical considerations on alloying design. The second chapter, "Introduction of the Biofunctions into Traditional Metallic Biomaterials," describes methods of introducing antibacterial function, MRI

compatibility, and radiopacity into traditional metallic biomaterials. Chapters 3–5 discuss the development of Mg-, Fe-, and Zn-based degradable metallic biomaterials, respectively, and explain the complete degradation of biomedical magnesium alloys in body fluid. The sixth chapter, “Development of Bulk Metallic Glasses for Biomedical Application,” provides an overview on various alloy systems characterized by amorphous structure, high strength, and good biocompatibility. The seventh chapter, “Development of Bulk Nanostructured Metallic Biomaterials,” discusses different nanostructured/ultrafine-grained metallic biomaterials, whereas the eighth chapter, “Titanium Implants Based on Additive Manufacturing,” demonstrates the new advanced additive manufacturing technology of fabricating titanium alloy implants. The ninth chapter, “Concluding Remarks on Revolutionizing Metallic Biomaterials,” discusses the future development direction of revolutionizing metallic biomaterials toward multifunctions and intelligentization.

The contributors to this book are Yufeng Zheng (Chapters 1, 2, 4, 5, and 9), Zhigang Xu (Chapter 3), Junqiang Wang (Chapter 6), Xiaoxue Xu (Chapter 7), and Hong Cai (Chapter 8). Special thanks are given to my students, namely, Yuanhao Wu, Dr Kejin Qiu, Wei Yuan, Tao Huang, and Meng Zhou, for their assistance in preparing the manuscript. Additionally, I would like to acknowledge the support by National Key Technologies Research and Development Program of China (Grant No. 2016YFC1102400 and 2016YFC1102402), National Key Technologies Research and Development Program of China (Grant No. 2016YFC1000900 and 2016YFC1000903), National Natural Science Foundation of China (Grant No. 31170909 and 51361165101), Beijing Municipal Science and Technology Project (Z141100002814008), NSFC/RGC Joint Research Scheme (Grant No. 51361165101 and 5161101031), and NSFC-RFBR Cooperation Project (Grant No. 51611130054).

Finally, we hope that this book will give its readers valuable insight into future directions of metallic biomaterials and biodevices and their innovative manufacturing technology. Given the diversity of topics covered, this book can be read as a reference by both university students and researchers from various backgrounds such as chemistry, materials science, physics, pharmacy, medical science, and biomedical engineering who are seeking an overview of state-of-the-art metals and alloys with biomedical applications.

Y.F. Zheng

Beijing, China
September 10, 2016


About the Authors




Yufeng Zheng is Professor in the Department of Materials Science and Engineering at Peking University, China. He started his research career at Harbin Institute of Technology in China after having obtained his PhD in materials science there. In 2004, he moved to Peking University and founded the Laboratory of Biomedical Materials and Devices at the College of Engineering. He was a winner of the National Science Fund for Distinguished Young Scholars in 2012. He has published more than 360 scientific publications including eight books and seven book chapters.



Xiaoxue Xu is Macquarie University Research Fellow in the Department of Chemistry and Biomolecular Sciences at Macquarie University, Australia. After she received her PhD in Materials Science and Engineering from the University of Western Australia, she worked there as Research Assistant Professor in the School of Chemical and Mechanical Engineering. She joined Macquarie University in 2014 and her research focuses on nano-structured biomaterials.



Zhigang Xu is Senior Research Scientist in Department of Mechanical Engineering at North Carolina A&T State University, USA. He is also affiliated to NSF Engineering Research Center for Revolutionizing Metallic Biomaterials, USA. He received his PhD in Mechanical Engineering from North Carolina A&T State University and then continued his research there as a faculty. He leads a Mg-alloy processing research group and Mg-based alloy design and processing project.



Junqiang Wang is Professor in Ningbo Institute of Materials Technology & Engineering, Chinese Academy of Sciences. He received his PhD in Condensed Matter Physics from Institute of Physics, Chinese Academy of Sciences. From 2010 to 2014 he worked as Research Associate in Tohoku University, Japan and University of Wisconsin-Madison, USA. He joined the Ningbo Institute of Materials Technology & Engineering in 2014 and was awarded the support of 100 Talents Program of Chinese Academy of Science. His research focused on fabrication and applications of metallic glasses.



Hong Cai is Associate Professor in Department of Orthopedics at Peking University Third Hospital, China. He worked over 10 years as Attending in orthopedics. During that period, he also worked sometime as Clinical Fellow at Seoul University, Korea, University of Western Ontario, Canada and Rush University Medical Center, USA. His research interest is design and development of new implants and 3D printing in orthopedics.

1

Introduction

1.1 Traditional Metallic Biomaterials

Traditional metallic materials have been typically used in medical applications such as orthopedic implants, dental applications, intravascular stents, and prosthetic heart valves. Compared with nonmetallic biomaterials, metallic biomaterials possess superior mechanical properties such as yield strength, ductility, fatigue strength, and fracture toughness [1], which are more suitable for load-bearing without large and/or permanent deformation. Application of metallic biomaterials goes back 100 years; in fact it is reported that a gold (Au) plate was used in the repair of cleft-palate defects as early as in 1565 [2]. Since then, a large number of metals and alloys, such as silver (Ag), platinum (Pt), palladium (Pd), tantalum (Ta), copper (Cu), nickel (Ni), zinc (Zn), aluminum (Al), magnesium (Mg), iron (Fe), carbon steels, stainless steels, cobalt–chromium (Co–Cr) alloys, titanium (Ti) and its alloys, and Nitinol (NiTi alloys), have been introduced into human body [3]. However, practice has shown that most of them are not perfect for implants in the human body due to various factors, such as insufficient mechanical properties, inferior corrosion resistance, and/or inadequate biocompatibility.

More recently, metallic biomaterials with better balance between good mechanical properties, a good corrosion resistance, and an excellent biocompatibility were developed. The common examples of these metallic biomaterials are type 316L stainless steel (316L SS), Co–Cr alloys, and Ti and its alloys [4]. These alloys have been approved for medical devices and surgical implants by the American Society for Testing and Materials (ASTM), and their mechanical properties are listed in Table 1.1. The 316L SS contains 0.03 wt% C, 17–19 wt% Cr, 13–15 wt% Ni, and 2–3 wt% Mo; the high Cr content gives it good resistance to a wide range of corrosive solutions. Due to its relatively low cost, availability, and easy processing, 316L SS has been employed successfully in the human body in contact with tissues and bones for several decades [6]. However, the wear resistance of 316L SS is poor, which makes it less suitable to be used as an artificial joint, because the excessive wear will lead to a rapid loosening. Compared with 316L SS, Co–Cr alloys exhibit a better wear resistance and an excellent corrosion resistance, even in chloride environments [7, 8]. Table 1.1 shows that their mechanical properties are also superior. The range of Co–Cr alloys used in clinical applications includes

Table 1.1 Mechanical properties of traditional metallic biomaterials.

Materials	Elastic modulus (GPa)	Yield strength (MPa)	Tensile strength (MPa)	Elongation (%)	ASTM Standard
Wrought 316L SS	190	190–690	490–1350	12–40	F138
Cast Co–28Cr–6Mo	210–253	450	655	8	F75
Wrought Co–20Cr–15W–10Ni (L605)	210	310–379	860–896	30–45	F90
Wrought Co–35Ni–20Cr–10Mo (MP 35N)	200–300	241–1586	793–1793	8–50	F562
Wrought Co–20Ni–20Cr–3.5Mo–3.5W–5Fe	—	276–1310	600–1586	12–50	F563
CP Ti (grade 1–4)	105	170–483	240–550	15–24	F67
Wrought Ti–6Al–4V ELI	110	760–795	825–860	8–10	F136
Wrought Ti–6Al–4V ELI	110	825–869	895–930	6–10	F1472
Cast Ti–6Al–4V	110	758	860	8	F1108
Wrought Ti–3Al–2.5V	—	517–714	621–862	10–15	F2146
Wrought Ti–6Al–7Nb	105	800	900	10	F1295
Wrought Ti–13Nb–13Zr	79–84	345–725	550–860	8–15	F1713
Wrought Ti–12Mo–6Zr–2Fe	74–85	897	931	12	F1813
Wrought Ti–15Mo	—	483–552	690–724	12–20	F2066
Wrought Ni–Ti	48	—	551	10	F2063

Elastic modulus data from Ref. [4, 5].

wrought and cast alloys. However, the elastic modulus of Co–Cr alloys (220–230 GPa) is similar to that of 316L SS (210 GPa), and both of them are much higher than that of cortical bone (20–30 GPa), leading to stress shielding in the adjacent bone and resulting in a final failure of implantation [3, 4]. Compared with 316L SS and Co–Cr alloys, Ti and its alloys exhibit lower modulus of 55–110 GPa, which is close to the bone. In addition, the passive film of TiO₂ on the surface of Ti and Ti alloys gives them excellent corrosion resistance. Therefore, Ti and its alloys have been selected as the best among the aforementioned traditional metallic biomaterials for its excellent combination of mechanical properties, corrosion resistance, and biocompatibility [9].

1.2 Revolutionizing Metallic Biomaterials and Their New Biofunctions

1.2.1 What are Revolutionizing Metallic Biomaterials?

According to Williams [10], the performance of any biomedical materials is controlled by two characteristics: biofunctionality and biocompatibility. Following this paradigm, many of the metallic materials used in the human body in the past have been extremely limited due to their insufficient biofunctionality and/or inferior biocompatibility [3]. Revolutionizing metallic biomaterials should have not only an excellent biocompatibility but also a specific biofunction in order to match the requirements in a variety of applications. Therefore, the revolutionizing metallic biomaterials researched and developed in recent years have various biofunctions. An interaction between the metallic biomaterials and the host is shown in Figure 1.1.

1.2.2 Antibacterial Function

The most serious complication in implantation surgery is bacterial infection. However, the traditional metallic biomaterials usually do not possess antibacterial function. Therefore, in the past few decades, the bacterial colonization and antibacterial activity on metallic implant materials have been reported under *in vitro* and *in vivo* tests [11–20]. The antibacterial function of metallic biomaterials is based on the antibacterial effect of the alloying elements, such as Ag, Cu, Zn, Co, Ni, Fe, Al, Sn, and Mg [21]. And in the current research of antibacterial metallic biomaterials, Ag and Cu are the commonly used alloying elements.

The metals Ag and Cu have antibacterial functions against a broad spectrum of microorganisms and their effects depend on their doses [22, 23]. The medical uses of Ag include its incorporation into wound dressing and as an antibacterial coating on medical devices. There is little evidence to support the application of wound dressings containing Ag sulfadiazine or Ag nanoparticles for external infections [24–26]. The use of Ag coatings on urinary catheters and endotracheal breathing tubes has been reported [27, 28], which may reduce the incidence of catheter-related urinary tract infections and ventilator-associated pneumonia, respectively. Ag exhibits low toxicity in the human body, and minimal risk is expected due to clinical exposure by inhalation, ingestion, or dermal




Figure 1.1 Comparison between the traditional and revolutionizing metallic biomaterials. (Reproduced with permission.)

application [29]. The antibacterial action of Ag is dependent on the Ag ion, which is bioactive and in sufficient concentration readily kills bacteria *in vitro*. Ag and Ag nanoparticles are used as an antibacterial agent in a variety of industrial, healthcare, and domestic applications [30]. However, Ag is not an essential mineral in humans. There is no dietary requirement for Ag, and the chronic intake of Ag products can result in an accumulation of Ag or silver sulfide particles in the skin [31].

Unlike Ag, Cu is a trace metal and an essential component of several enzymes; the adult body contains between 1.4 and 2.1 mg of Cu per kg of body weight [32]. More importantly Cu can be metabolized and is much safer for the human body than Ag. As a matter of fact, in a proper range, the Cu can be excreted in the bile [15]. Cu and its alloys can be considered as natural antibacterial materials [33]. Numerous antibacterial efficacy studies indicated that Cu alloy contact surfaces have natural intrinsic properties to destroy a wide range of bacteria, as well as influenza A virus, adenovirus, and fungi [34]. Some 355 Cu alloys were proven to kill more than 99.9% of disease-causing bacteria within just 2 h when cleaned regularly [35].

Therefore, with comprehensive consideration of the antibacterial characteristic of Ag and Cu, the new antibacterial metallic biomaterials are always focused on the traditional metallic biomaterials containing Ag and/or Cu. There is a large number of studies on Ag- or Cu-bearing antibacterial stainless steels [12–14, 36–46], Ti–Ag or Ti–Cu alloys with antibacterial properties [15, 16, 47, 48], and other antibacterial metallic biomaterials containing Ag or Cu [18–20, 49, 50].

1.2.3 Promotion of Osteogenesis

From the osteogenesis perspective, the aforementioned traditional metallic biomaterials are considered to be bioinert materials. Osseointegration, which is the process of bone healing and the formation of new bone, is the clinical goal of implant surgery. The implant and the bone cells are considered well osseointegrated when new bone cells form, proliferate, and differentiate on the implant [4]. In order to obtain a firm binding between the metallic implants and the surrounding bone, the bioactive interface must facilitate a better bone regeneration and expedited healing. There are many studies that focus on the surface modifications to gain an excellent bone regeneration ability. Some strategies experimented to improve bone integration of metallic implants are development of porous surface, coating of nanoceramic particles, hydroxyapatite coating, oxide coating, and thermal heat treatment of surfaces.

By using rapid prototyping (RP) technique and electrodeposition method, Lopez-Heredia *et al.* [51] have built porous Ti scaffolds with a calcium phosphate (CaP) coating and then studied their osteogenic property. The subcutaneous implantation results showed the presence of mineralized collagen but not mature bone tissue. Even so, the study opened up the possibility of using high-strength porous scaffolds with appropriate osteoconductive and osteogenic properties to reconstruct large skeletal parts in the maxillofacial and orthopedic fields. By using another technique called laser engineered net shaping (LENS™), Balla *et al.* [52] have demonstrated that the modulus of porous Ta can be tailored between 1.5 and 20 GPa by varying its porosity. And the *in vitro* biocompatibility tests showed excellent cellular adherence, growth, and differentiation with abundant extracellular matrix formation on porous Ta structures, which indicated a promotion in biological fixation. On the modified microarc oxidation (MAO)-treated Ti implants surface, fast osteoid deposition comprising high content of Ca, P, C, and N was found in the work of Ma *et al.* [53]. MAO-treated Ti materials have been proved to exhibit good CaP inducement capability *in vivo*, which could accelerate bone tissue growth and shorten the osseointegration time. A highly controlled and reproducible electrochemical polishing process can be used to pattern and structure the surface of Ti-6Al-4V alloy at both the nano- and microscale [54]. The treated surface with a nanoscale TiO₂ layer influenced the program of cellular differentiation culminating in osteogenesis. Chai *et al.* [55] have evaluated the *in vitro* and *in vivo* osteogenesis of a β -tricalcium-phosphate (TCP)-coated Mg alloy. The *in vitro* cell tests showed that the β -TCP coating provided the Mg alloy with a significantly better surface cytocompatibility, and *in vivo* results also confirmed that the β -TCP coating exhibited greatly improved osteoconductivity and osteogenesis in the early 12 weeks postoperative period. To mimic the extracellular microenvironment of bone, Hu *et al.* [56] constructed a bioactive multilayered structure of gelatin/chitosan pair, containing bone morphogenetic protein 2 (BMP2) and fibronectin (FN) on the Ti-6Al-4V surface via a layer-by-layer assembly technique. The *in vivo* tests demonstrated that the multilayer coated Ti-6Al-4V implants promoted the bone density and new bone formation around them after implantation for 4 and 12 weeks, respectively, and showed that the coatings are beneficial for osteogenesis and integration of

implant/bone. In another study, they prepared the apatite/gelatin nanocomposite onto Ti substrates via a coprecipitation method [57]. The results showed that the deposition of apatite/gelatin nanocomposite improved bone density and bone–implant contact rate significantly, and that deposition enhanced the bone osseointegration of Ti-based implants. Bone tissue regeneration in load-bearing regions of the body requires high-strength porous scaffolds capable of supporting angiogenesis and osteogenesis. Gotman *et al.* [58] produced the porous Nitinol scaffolds with a regular 3D architecture resembling trabecular bone using an original reactive vapor infiltration technique. The results of co-culture system of microvascular endothelial cells demonstrated the formation of prevascular structures in trabecular Nitinol scaffolds. It suggested that the strong osteoconductive load-bearing trabecular Nitinol scaffolds could be effective in regenerating damaged or lost bone tissue. Besides the aforementioned methods, Kim *et al.* [59] studied the synergistic effects of nanotopography and co-culture with human umbilical endothelial cells (HUVECs) on osteogenesis of human mesenchymal stem cells (hMSCs). The rational design and fabrication of bone tissue-like nanopatterned matrix are shown in Figure 1.2. Their findings suggested that the nanotopography contributed to the osteogenesis more than co-culture with HUVECs did. However, what is more important than the results is this study provided a new insight on the importance of tissue-inspired nanotopography and co-culture systems in designing engineered platforms for stem cell-based bone tissue engineering, as well as for the fundamental study of stem cell biology. Lee *et al.* [60] studied the bone regeneration around *N*-acetyl




Figure 1.2 Rational design and fabrication of bone tissue-like nanopatterned matrix with various groove sizes. (a) Graphical illustrations and SEM images of *ex vivo* bone tissue. The insert is a high-magnification image of the region indicated by the white arrow, showing the well-aligned nanostructures in bone tissue. (b) A photograph and (c) SEM images of PUA matrix nanotopography on glass slide. The spacing ratio is the ratio of the width to the spacing of nanogrooves. (d) Schematic illustration showing the engineered platforms consisting of hMSCs, HUVECs, and nanopatterned matrix. (Kim *et al.* 2013 [59]. Reproduced with permission of Elsevier.)

cysteine-loaded nanotube Ti (NLN-Ti) dental implant in a rat mandible. The results of μ -computed tomography revealed an increase of newly formed bone volume and bone mineral density in the mandibles of Sprague Dawley rats. The immunohistochemical analysis showed a significantly higher expression of BMP-2, BMP-7, and heme oxygenase-1 and reduced expression of receptor activator of nuclear factor- κ B ligand. All the data indicate that NLN-Ti implants enhance osseointegration and highlight the value of the small animal model in assessing diverse biological responses to dental implants.

Mg alloys have been investigated in different fields of medicine and represent a promising biomaterial for implants due to characteristics like bioabsorbability and osteoinduction. Lensing *et al.* [61] tested a bioabsorbable Mg alloy serving as total ossicular replacement prostheses. The *in vivo* results revealed a considerable degradation of implants and obvious bone formation was found 3 months after implantation. Although the Mg alloy corroded before completing the bone reconstruction in time, the increased osteoinduction on the stapes base plate resulted in a tight bone-implant bonding. Therefore, the authors think that the combined application of Mg implant and coating would be a promising solution for improving the bone integration of implants.

In a recent study, Qiao *et al.* [62] reported the stimulation of bone growth following Zn incorporation into biomaterials. Zn is incorporated into the sub-surface of TiO₂ coatings (Zn-implanted coatings) by plasma immersion ion implantation and deposition (PIII&D), with the “bulk-doped” coatings prepared by plasma electrolyte oxidation control; the schematic representation of the two Zn incorporation strategies are shown in Figure 1.3. The results revealed that the Zn-implanted coatings resulted in a significant improvement of osteogenesis *in vitro* and *in vivo* compared with the “bulk-doped” coatings. Molecular and cellular osteogenic activities demonstrate that rat BMSCs cultured on the Zn-implanted coatings have higher ALP activity and upregulated osteogenic-related genes (OCN, Col-I, ALP, Runx2). *In vivo* osseointegration studies also showed an early-stage




Figure 1.3 Schematic representation of the two Zn incorporation strategies: bulk incorporation and surface incorporation. (Qiao *et al.* 2014 [62]. Reproduced with permission of Elsevier.)

new bone formation and a larger bone contact ratio (12 weeks on the rat model) on the Zn-implanted coating.

1.2.4 Reduction of In-stent Restenosis

Cardiovascular stent materials should possess not only a good cell affinity but also a mechanical property similar to that of blood vessels. Coronary stent implantation has been proven to be an effective technique for the prevention of restenosis in native coronary vessels compared with angioplasty alone. Despite advances in polymer and drug technology, the underlying stent platform remains a key determinant of the clinical outcomes [63]. Currently, the restenosis rates after bare-metal stent (BMS) implantation are still as high as 20–40% at 6 months [64]. Drug-eluting stents (DESs) were shown to be safe and feasible in reducing restenosis [65, 66], but their efficacy and safety have not been confirmed in all clinical settings, especially with regard to treating in-stent restenosis. So reducing the in-stent restenosis remains to be a big challenge. From the angle of biomaterials, the stents should promote the proliferation of vascular endothelial cells (VECs), which hereby accelerate the process of revascularization. In the meantime, they obviously inhibit the proliferation of vascular smooth muscle cells (VSMCs) [17].

Ren *et al.* [67] studied the effect of trace amount of Cu ions released from Cu-bearing stainless steel on reduction of in-stent restenosis. The *in vitro* experimental results proved that this Cu-bearing steel could not only inhibit the proliferation of VSMCs for reducing the formation of thrombosis but also promote the proliferation of VECs needed for the revascularization. However, because there were no *in vivo* experimental results to support it, further animal study should be done.

Over the last 10 years, considerable efforts have been made to develop fully bioresorbable devices called bioresorbable scaffolds (BRSs). BRS technology has gradually matured, and there are numerous devices available, which are currently undergoing preclinical or clinical testing. Mg is an attractive alloy for this concept [68]. The first generation of bioabsorbable metal scaffolds (AMS-1; Biotronik AG, Bülach, Switzerland) was made from a WE43 alloy without drug elution. In porcine coronary arteries, the neointimal tissue proliferation was significantly less in the stented segments with the Mg alloy scaffold as compared with a control group of stainless steel stents [69]. Compared with AMS-1 strut thickness being 165 μm , the strut thickness of DREAMS first generation (DREAMS 1G) was reduced to 120 μm . Moreover, to reduce neointimal growth, the DREAMS was coated with a 1 μm bioresorbable poly(lactide-co-glycolide acid) (PLGA) polymer matrix containing the antiproliferative drug paclitaxel ($0.07 \mu\text{g mm}^{-2}$) [70]. Then the DREAMS second generation (DREAMS 2G) with radiopaque markers at both ends (made from Ta) was developed. As a result, DREAMS 2G has slower dismantling and resorption rate. To further reduce the neointima formation, the DREAMS 2G was coated with a bioresorbable polylactic acid polymer (7 μm) featuring sirolimus at a dose of $1.4 \mu\text{g mm}^{-2}$. Combining the material characteristics of Mg and the antiproliferative featuring of sirolimus, the DREAMS 2G showed a significant reduction of in-stent restenosis.

1.2.5 MRI Compatibility

Magnetic resonance imaging (MRI) is a technology developed in medical imaging that is probably the most innovative and revolutionary other than computed tomography. MRI has a wide range of applications in medical diagnosis and there are estimated to be over 25 000 scanners in use worldwide [71]. However, most of the currently used implants for cochlear implants, intravascular stents, cardiac pacemakers, and artificial joints are challenged by their unsatisfactory MRI compatibility, because the implants contain ferromagnetic elements [72]. MRI diagnosis is inhibited by the presence of metallic implants, because they become magnetized in the intense magnetic field of the MRI instrument and may produce image artifacts and therefore prevent accurate diagnosis [73, 74]. Hence, improving the MRI compatibility of novel biomedical metallic materials for implants is a very important research topic.

The two trends of development of MRI interventional tools are producing new material with no artifacts and MRI visualizing and guiding of percutaneous devices [75]. Generally, the artifacts affected by MRI decrease with the magnetic susceptibility of the implants [76]. The susceptibilities of selected weakly magnetic metals and alloys are listed in Table 1.2, with water and human tissues as control. In recent years, some studies have focused on the novel MRI-compatible Mg, Zr, and Nb alloys for implants [72, 74, 78–84]. More details can be seen in Section 2.2.

Table 1.2 Susceptibilities of selected weakly magnetic metals and alloys [77].

Materials	Density/ ρ (10^3 kg m^{-3})	Susceptibility/ χ ($\times 10^{-6}$)
Water (37°C)	0.933	-9.05
Human tissues	~(1.0 to 1.05)	~(-11.0 to -7.0)
Au	19.32	-34
Cu	8.92	-9.63
Mg	1.74	11.7
Zr	6.49	109
Mo	10.22	123
Ta	16.65	178
Ti	4.54	182
Nb	8.57	237
Pt	21.45	279
Pd	12.02	806
Nitinol (50% Ti, 50% Ni)	6.5	245
Stainless steel (nonmagnetic, austenitic)	8.0	3520–6700

Source: Reproduced with permission of The American Society of Physicist Medicine.

1.2.6 Radiopacity

Radiopacity is an important property of medical devices such as vascular stents and catheters during placement and deployment. Especially in cardiovascular stents, it is essential to monitor the catheter's progression in the vascular branches under an X-ray fluoroscopy, therefore, avoiding invasive procedures on patients [75]. Usually, the absorption of X-rays depends on the number of protons of the elements being used, and the metals with higher X-ray absorption coefficient will become more radiopaque during the interventional operation. There are various methods to improve radiopacity, such as alloying, coating, banding, and addition of contrast agents [85]. In order to obtain the optimal comprehensive performance, the researchers pay more attention to the stent materials and coatings. More details can be found in Section 2.3.

1.2.7 Self-Adjustment of Young's Modulus for Spinal Fixation

Applications

The implantation of metallic rods plays an important role in the treatment of spinal diseases and conditions such as scoliosis, spondylolisthesis, and spinal fractures [86]. Due to the special function of the spine, an implant with a higher Young's modulus is expected from the viewpoint of surgeons for better workability during operation, while a lower Young's modulus is desired from the viewpoint of patients for preventing stress shielding effects. Therefore, if there existed any metallic biomaterials with changeable Young's modulus, the conflicting requirements between surgeons and patients may be satisfied at the same time.

Based on this purpose, Nakai *et al.* [87] proposed a solution to satisfy this conflicting requirement. For certain metastable β -type Ti alloys, a nonequilibrium phase, such as α' , α'' , or ω , appears during deformation. If the deformation-induced phase shows a higher Young's modulus than the matrix, the Young's modulus of the deformed part increases, while that of the nondeformed part remains low. Thus the springback can be suppressed by deformation-induced phase transformation during bending in the course of surgery, and a low Young's modulus can be retained for the benefit of the patient, as can be seen in Figure 1.4. Besides, their group studied the Ti–Zr, Ti–Mo, and Ti–Cr alloys with changeable Young's moduli for spinal fixation applications [88–91]. The results showed that the Ti–30Zr–3Cr–3Mo, Ti–17Mo, and Ti–12Cr alloys were promising candidates for spinal fixation applications.

1.3 Technical Consideration on Alloying Design of Revolutionizing Metallic Biomaterials

1.3.1 Evolution of Mechanical Properties with Implantation Time

For many decades, the traditional metallic biomaterials have always been used extensively for surgical implants due to good formability, high strength, and high resistance to fracture. However, the surgical implants fabricated with these traditional metallic biomaterials are permanent implants, due to their bioinert




Figure 1.4 Concept of changeable Young's modulus of implant rods during surgery. (Nakai *et al.* 2011 [87]. Reproduced with permission of Elsevier.)

characteristics. Therefore, during their service, their mechanical properties were hardly changed with the prolongation of implantation time. But sometimes the implantation failure would occur because these traditional metallic biomaterials, which have much higher stiffness than bone, prevent the needed stress being transferred to adjacent bone, resulting in bone resorption around the implant and consequently to implant loosening [92].

With the advance of biomaterials science, the new biomaterials possess more matchable properties to human tissues than ever before. Their stiffness, strength, and fracture toughness are shown in Figure 1.5 [93]. Table 1.3 also lists the mechanical properties of some revolutionizing metallic biomaterials with various biofunctions.

Revolutionizing metallic biomaterials not only possess unique biofunctionality but also feature capability to evolve their mechanical properties during their implantation time. Over recent years, a new class of metallic biomaterials named as biodegradable metals (BMs) has been widely studied by materials scientists. The BMs are expected to corrode gradually *in vivo*, with an appropriate host response elicited by released corrosion products, and then dissolve completely upon fulfilling the mission to assist with tissue healing with no implant residues [100]. Two classes of BMs have been proposed: Mg- and Fe-based alloys. They are envisaged in three targeted applications: orthopedic, cardiovascular, and pediatric implants. Given that the BMs are prone to corrode in human body environment, the mechanical integrity of BMs would change with the implantation time, as shown in Figure 1.6. During the first 2–3 weeks postfracture, the soft callus forms, which corresponds roughly to the time when the fragments are no longer moving freely. This early soft callus can resist compression but shows tensile properties similar to the fibrous tissue of which the ultimate tensile strength and elongation at rupture are 4–19 MPa and 10–12.8%, respectively [101]. Hence the mineralization of the soft callus proceeds from the fragment ends toward the center of the fracture site and forms a hard callus, which has regained enough strength and rigidity to allow low-impact exercise at the end of the repair phases [101, 102]. The time to achieve the hard bone union varies greatly according to the fracture configuration and location, status of the adjacent




Figure 1.5 Comparison of (a) stiffness, (b) strength, and (c) fracture toughness for metals, technical ceramics, composites, and fiber-reinforced plastic with respect to bone. CF, carbon fiber; GF, glass fiber; PA12, polyamide12; PC, polycarbonate; PE, polyethylene; PEEK, poly ether ether ketone; PLGA, poly(lactide-co-glycolide acid); PLLA, poly(L-lactic acid); PP, polypropylene; PSU, polysulfone; PTFE, polytetrafluoroethylene; and PUR, polyurethane. (Mantripragada *et al.* 2013 [93]. Reproduced with permission of John Wiley & Sons.)

Table 1.3 Comparison of mechanical properties between some revolutionizing and traditional metallic biomaterials.

Elastic modulus (GPa)	Microhardness (HV)	Yield strength (MPa)	Ultimate tensile strength (MPa)	Elongation (%)	Biofunctional improved property	References
19.9±1.8	52.7–76.4	107.9±12.3	—	—	—	[94, 95]
190	—	190–690	490–1350	12–40	—	ASTM F138
—	142–154	255–285	562–593	58–68	Antibacterial	[37]
—	—	—	—	—	Antibacterial	[44]
—	—	850–1480	900–1560	17–30	Enhanced mechanical and fatigue properties	[96]
105	—	170–483	240–550	15–24	—	ASTM F67
—	—	640	710	14	Enhanced mechanical properties	[97]
—	—	790	950	14	Enhanced mechanical properties	[98]
110	—	760–795	825–860	8–10	—	ASTM F136
—	—	1310	1370	12	Enhanced fatigue properties	[99]
68–79	—	650–770	800–1000	8–18	Self-adjustment of Young's modulus	[88]
73–84	—	500–730	725–850	15–25	Self-adjustment of Young's modulus	[89]
—	—	—	710	17.6	Shape memory effect, superelasticity, and antibacterial	[18]
44–46	27–43	—	165–210	13–20	Biodegradable, antibacterial	[19]
—	—	—	—	—	Biodegradable, antibacterial	[20]
1.5–20	—	—	—	—	Promote enhanced/early biological fixation	[52]




Figure 1.6 The schematic diagram of the degradation behavior and the change of mechanical integrity of BM implants during the bone healing process. (Zheng *et al.* 2014 [100]. Reproduced with permission of Elsevier.)

soft tissues, and patient characteristics (e.g., age, health status, concurrent injuries/diseases). According to Perkin's classification of fracture healing, a spiral fracture in the upper limb unites in 3 weeks and consolidates in 6 weeks. The fracture healing time doubles for a transverse fracture and doubles again for the lower limb. As can be seen in Figure 1.7, the mechanical support should be sustained for 12–24 weeks depending on the clinical conditions.

Currently, the reported Mg alloy stents and bone implants indicate a relatively faster degeneration of mechanical properties before/during the tissue remodeling process than expected. For example, the reported Mg-based BM stents completely degraded within 4 months and the mechanical integrity of the stent was lost much faster than predicted. In the future, surface coating could be used as a remedy to extend the mechanical integrity of Mg-based BM stents. In the case of Fe-based BM stents, they exhibit good mechanical support during 4 months, and much slower loss of mechanical integrity of stent occurs. In the near future, research should consider how to control the speed of biodegradation.

1.3.2 Biocorrosion or Biodegradation Behavior and Control on Ion Release

For traditional metallic biomaterials, good corrosion resistance is one of the major factors determining their biocompatibility. When they are implanted in the human body, a highly electrolytic environment, implants become the site of electrochemical reactions and lead to the release of metal ions into the surrounding tissues [103]. The traditional metallic biomaterials are prone to release metal ions